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taller risk to develop a cancer. The elderly patients, because 
of the presence of concomitant pathologies, they set to the 
clinician particular problems and limitations in the 
therapeutic planning. Several groups have reported the value 
of combination of conservative surgery and 
radiochemotherapy or radical radiotherapy alone in patients 
affected by bladder cancer. In this study we have 
retrospectively analyzed the prognostic factors influencing 
survival and relapse free-survival after radiotherapy following 
transurethral resection (TURB) for bladder cancer.  
 
Material and Methods: Between May 2013 and December 
2014, 33 patients with bladder cancer have been treated at 
the Operative Unity of Radiotherapy and Radiobiology, 
Hospital of Catanzaro. Of these, 19 patients were treated 
with radiotherapy alone (RT) and nine with platin based 
radio-chemotherapy (RCT) after TURB. Overall survival (OS) 
and Relapse-Free Survival (RFS) were analyzed with the 
Kaplan and Meyer methods. Comparisons were made using 
the log-rank test. In the analysis, we proposed the following 
prognostic factors as affecting the development of relapse 
after initial treatment: Univariate analysis was performed for 
age, grade, R-status after initial TURB, T-category relevant 
to the endpoints initial response, survival and bladder 
preservation. 
 
Results: Median age was 78 years (range 66-90 years), while 
the median follow-up is 15 months (range 5-42 months). All 
patients were treated with three-dimensional conformal 
therapy (3D-CRT). The total dose of radiotherapy ranged 
5040 cGy to 6000 cGy. Complete remissions were achieved at 
57% after RT and TURB. Toxicity was acceptable. Further 
significant prognostic factors were pT-category and R-status. 
For all patients survival was 31% after 2 years and 25% at 4 
years, while the relapse-free survival rates were 19% and 15% 
at 2 and 4 years, respectively. In the univariate analysis the 
only significant factor for survival and relapse-free survival 
and bladder preservation was the R-status after initial TURB 
 
Conclusion: In conclusion, treatment of bladder cancer by 
TURB and RT alone is an alternative to primary cystectomy, 
for the elderly patients. Initial TURB is recommended to be 
as radical as possible. 
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Purpose or Objective: to compare 2 multifraction 
radiotherapy (RT)schedules in the palliation of painful bone 
metastases in elderly patients, assessed at baseline with the 
Cumulative Illness Rating Scale for Geriatrics (CIRS-G). 
 
Material and Methods: 132 elderly patients were analyzed. 
Seventy-seven patients received a single 8Gy in single 
fraction and 55 received 20 Gy in 5 fractions. The choice of 
the treatment schedule was related to comorbidity, 
disability, target size and compliance. Pain intensity was 
measured with Numeral Rating Scale (NRS: 0 = no pain; 10 = 
high pain). Complete response was defined a pain reduction > 
3 of three points, partial response as a pain reduction ≥2 (2 ≤ 
pain reduction ≤ 3), no response was defined by pain score < 
2. Pain evaluation was recorded at baseline and at 1-4-8 
weeks after completing RT. 
 
Results: overall response: 90.3% in 8 Gy arm (49.8% complete 
and 40.5% partial), 94.6% in 20 Gy arm (44.6% complete and 
50%partial). No high grade toxicity were reported. The relief 
of pain was attained faster with single fraction (p-value ~ 
0.2). We observed maximum response of pain control after 8 
weeks and no significant differences were noted between 
two groups. The re-treatment rate was 17.6% vs 11.1% 
respectively. 
 
Conclusion: no significant differences between the two arms 
in terms of pain response, pain control and toxicity. Our 
experience showed that not influenced by age, but in the 
elderly, life expectancy, comorbidities evaluated with the 
CIRS-G, and compliance, are crucial in selecting of shorter 
treatment. 
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Purpose or Objective: To evaluate stereotactic body 
radiation therapy (SBRT) for oligometastatic lung tumors in 
patients 75 years old or older. 
 
Material and Methods: Between 2002 and 2015, 24 elderly 
patients with 34 lung metastases were treated using SBRT at 
our institution. SBRT procedure involved: Slow-scan 
computed tomography (CT) simulation with immobilization 
devices, contouring the target volume in 3 sets of CTs, 
superimposing the volumes in the planning system to 
represent the internal target volume and dose calculation 
using heterogeneity correction. Radiation delivery with 
multiple static planar or non-coplanar beams and arc therapy 
assured conformal dose distribution and steep fall-off of the 
radiation. The prescribed dose was 3 fractions of 15 Gy each 
(90%) given in 6-10 days or a single 30-Gy fraction (10%), with 
at least 95 % of the ITV covered by the 95% isodose line. 
Dosimetric constraints were set for surrounding organs at 
risk. Repeated cone-beam CT were used to verify daily 
positioning. Toxicity and radiologic response were assessed in 
follow-up, using standardized criteria (RTOG and RECIST) and 
analyzed retrospectively. Survival rates and toxicities were 
calculated by the Kaplan-Meier method. 
 
Results: Median patient age was 79 years (75-85). The origin 
of the metastases was: non-small cell lung cancer (53 %), 
colorectal adenocarcinoma (24 %), urotelial tumors (8.5 %), 
thyroid carcinoma (8.5 %), endometrial adenocarcinoma (3%) 
and parotid tumor (3%). All patients had good performance 
status at the moment of treatment (ECOG PS 0-1). Fifty-six 
percent of all patients also received systemic treatment 
before or after SBRT. Mean tumor volume was 10.7 cm3 (0.5-
106). The only acute toxicity reported was rib pain, grade 2, 
in 1 patient. No grade > 3 acute or any chronic toxicities 
were identified. The median follow-up was 11 months (1-60). 
The 6, 12 and 18 month overall survivals were 97, 88 and 85 
%. Local control in the irradiated volume is 97 %, the only 
failure occurring in a patient who also had distal progression 
from colon adenocarcinoma. 
 
Conclusion: SBRT is an excellent treatment option for lung 
oligometastasis in elderly patients. Our encouraging results 
are in line with those reported in recent literature for 
younger patients.  
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Purpose or Objective: Some recent data has questioned the 
impact of larynx preservation strategy on overall survival. 
The median age of patients in most major larynx preservation 
trials was 55-60 years with little representation of the older 
age group. The aim of this study is to review the tolerance 
and outcomes of larynx preservation treatment in the older 
population (≥ 65). 
 
